This is because CML stem cells are not dependent on BCR-ABL activity [6], suggesting that there may be an oncogenic function of BCR-ABLp210 that can persist following inhibition of ABL kinase activity. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.